## Ronald S Swerdloff

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/518994/publications.pdf

Version: 2024-02-01

97 papers 8,926 citations

43 h-index 49773 87 g-index

102 all docs

102 docs citations

102 times ranked

5802 citing authors

#	Article	IF	CITATIONS
1	Testosterone Therapy in Men With Hypogonadism: An Endocrine Society* Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1715-1744.	1.8	1,050
2	Effects of Testosterone Treatment in Older Men. New England Journal of Medicine, 2016, 374, 611-624.	13.9	675
3	Transdermal Testosterone Gel Improves Sexual Function, Mood, Muscle Strength, and Body Composition Parameters in Hypogonadal Men1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2839-2853.	1.8	648
4	Long-Term Testosterone Gel (AndroGel) Treatment Maintains Beneficial Effects on Sexual Function and Mood, Lean and Fat Mass, and Bone Mineral Density in Hypogonadal Men. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2085-2098.	1.8	602
5	Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone. JAMA - Journal of the American Medical Association, 2017, 317, 708.	3.8	289
6	Long-Term Pharmacokinetics of Transdermal Testosterone Gel in Hypogonadal Men $<$ sup>1 $<$ /sup>. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 4500-4510.	1.8	287
7	American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Hypogonadism in Adult Male Patients—2002 Update. Endocrine Practice, 2002, 8, 439-456.	1.1	271
8	Long-Term Pharmacokinetics of Transdermal Testosterone Gel in Hypogonadal Men. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 4500-4510.	1.8	246
9	Effect of Testosterone Treatment on Volumetric Bone Density and Strength in Older Men With Low Testosterone. JAMA Internal Medicine, 2017, 177, 471.	2.6	241
10	Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. Lancet, The, 2006, 367, 1412-1420.	6.3	223
11	Reexamination of testosterone, dihydrotestosterone, estradiol and estrone levels across the menstrual cycle and in postmenopausal women measured by liquid chromatography–tandem mass spectrometry. Steroids, 2011, 76, 177-182.	0.8	196
12	Association of Testosterone Levels With Anemia in Older Men. JAMA Internal Medicine, 2017, 177, 480.	2.6	180
13	Neurobehavioral phenotype of Klinefelter syndrome. Mental Retardation and Developmental Disabilities Research Reviews, 2000, 6, 107-116.	3.5	176
14	Lessons From the Testosterone Trials. Endocrine Reviews, 2018, 39, 369-386.	8.9	173
15	Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clinical Endocrinology, 2001, 54, 739-750.	1.2	151
16	Significance of Apoptosis in the Temporal and Stage-Specific Loss of Germ Cells in the Adult Rat after Gonadotropin Deprivation 1. Biology of Reproduction, 1997, 57, 1193-1201.	1.2	140
17	Pharmacokinetics of Transdermal Testosterone Gel in Hypogonadal Men: Application of Gel at One Site Versus Four Sites: A General Clinical Research Center Study*. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 964-969.	1.8	136
18	Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels. Endocrine Reviews, 2017, 38, 220-254.	8.9	123

#	Article	IF	CITATIONS
19	Simultaneous Measurement of Serum Testosterone and Dihydrotestosterone by Liquid Chromatography–Tandem Mass Spectrometry. Clinical Chemistry, 2008, 54, 1855-1863.	1.5	121
20	Neuropsychological profiles of adults with Klinefelter syndrome. Journal of the International Neuropsychological Society, 2001, 7, 446-456.	1.2	114
21	Testosterone Treatment and Sexual Function in Older Men With Low Testosterone Levels. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3096-3104.	1.8	110
22	Lead Toxicity and the Hypothalamic-Pituitary-Testicular Axis. Biology of Reproduction, 1985, 33, 722-728.	1,2	109
23	Neuroprotective effects of testosterone treatment in men with multiple sclerosis. NeuroImage: Clinical, 2014, 4, 454-460.	1.4	107
24	Determinants of the Rate and Extent of Spermatogenic Suppression during Hormonal Male Contraception: An Integrated Analysis. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1774-1783.	1.8	106
25	Levonorgestrel Implants (Norplant II) for Male Contraception Clinical Trials: Combination with Transdermal and Injectable Testosterone. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3562-3572.	1.8	100
26	The Testosterone Trials: Seven coordinated trials of testosterone treatment in elderly men. Clinical Trials, 2014, 11, 362-375.	0.7	98
27	<i>In Vitro</i> Inhibition of Testosterone Biosynthesis by Ketoconazole. Endocrinology, 1985, 116, 1920-1925.	1.4	89
28	A New Combination of Testosterone and Nestorone Transdermal Gels for Male Hormonal Contraception. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3476-3486.	1.8	85
29	Suppression of Spermatogenesis in Man Induced by Nal-Glu Gonadotropin Releasing Hormone Antagonist and Testosterone Enanthate (TE) Is Maintained by TE Alone $<$ sup $>$ 1 $<$ sup $>$ 1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 3527-3533.	1.8	79
30	Association of Sex Hormones With Sexual Function, Vitality, and Physical Function of Symptomatic Older Men With Low Testosterone Levels at Baseline in the Testosterone Trials. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1146-1155.	1.8	79
31	The Effect of Testosterone on Cardiovascular Biomarkers in the Testosterone Trials. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 681-688.	1.8	79
32	Validation of a testosterone and dihydrotestosterone liquid chromatography tandem mass spectrometry assay: Interference and comparison with established methods. Steroids, 2008, 73, 1345-1352.	0.8	73
33	Macimorelin as a Diagnostic Test for Adult GH Deficiency. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3083-3093.	1.8	71
34	Aging Results in Attenuated Gonadotropin Releasing Hormone-Luteinizing Hormone Axis Responsiveness to Glutamate Receptor Agonist N-Methyl-D-Aspartate*. Journal of Neuroendocrinology, 2008, 10, 93-99.	1,2	67
35	Combined Transdermal Testosterone Gel and the Progestin Nestorone Suppresses Serum Gonadotropins in Men. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2313-2320.	1.8	65
36	Effect of testosterone replacement on measures of mobility in older men with mobility limitation and low testosterone concentrations: secondary analyses of the Testosterone Trials. Lancet Diabetes and Endocrinology,the, 2018, 6, 879-890.	5.5	64

#	Article	IF	CITATIONS
37	A Simple Selfâ€Report Diary for Assessing Psychosexual Function in Hypogonadal Men. Journal of Andrology, 2003, 24, 688-698.	2.0	62
38	Acceptability of a transdermal gel-based male hormonal contraceptive in a randomized controlled trial. Contraception, 2014, 90, 407-412.	0.8	59
39	A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2515-2531.	1.8	58
40	Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel. Aging Male, 2003, 6, 207-211.	0.9	52
41	Hormonal approaches to male contraception. Current Opinion in Urology, 2010, 20, 520-524.	0.9	51
42	Male Hormonal Contraception: Where Are We Now?. Current Obstetrics and Gynecology Reports, 2016, 5, 38-47.	0.3	49
43	Nuclear accumulation of estradiol derived from the aromatization of testosterone is inhibited by hypothalamic beta-receptor stimulation in the neonatal female rat Biology of Reproduction, 1984, 30, 388-396.	1.2	43
44	Reexamination of Pharmacokinetics of Oral Testosterone Undecanoate in Hypogonadal Men With a New Selfâ€Emulsifying Formulation. Journal of Andrology, 2012, 33, 190-201.	2.0	43
45	A Multicenter, Open-Label, Observational Study of Testosterone Gel (1%) in the Treatment of Adolescent Boys With Klinefelter Syndrome or Anorchia. Journal of Adolescent Health, 2014, 54, 20-25.	1.2	43
46	Effects of 28 Days of Oral Dimethandrolone Undecanoate in Healthy Men: A Prototype Male Pill. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 423-432.	1.8	43
47	The Stimulatory and Down-Regulatory Effects of a Gonadotropin-Releasing Hormone Agonist in Man*. Journal of Clinical Endocrinology and Metabolism, 1984, 58, 1084-1088.	1.8	40
48	Androgen Replacement Therapy. Annals of Medicine, 1997, 29, 365-370.	1.5	40
49	Functional role of progestin and the progesterone receptor in the suppression of spermatogenesis in rodents. Andrology, 2013, 1, 308-317.	1.9	39
50	Serum Testosterone (T) Level Variability in T Gel-Treated Older Hypogonadal Men: Treatment Monitoring Implications. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3280-3287.	1.8	38
51	Safety and Pharmacokinetics of Single-Dose Novel Oral Androgen $11-Methyl-19-Nortestosterone-17-Dodecylcarbonate in Men. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 629-638.$	1.8	38
52	Androgen deficiency and aging in men. Western Journal of Medicine, 1993, 159, 579-85.	0.3	37
53	Male Contraception: Clinical Assessment of Chronic Administration of Testosterone Enanthate. Journal of Developmental and Physical Disabilities, 1978, 1, 731-747.	3.6	35
54	Comparison of the single dose pharmacokinetics, pharmacodynamics, and safety of two novel oral formulations of dimethandrolone undecanoate ( <scp>DMAU</scp> ): a potential oral, male contraceptive. Andrology, 2017, 5, 278-285.	1.9	35

#	Article	IF	Citations
55	Spontaneous Expression of Inducible Nitric Oxide Synthase in the Hypothalamus and Other Brain Regions of Aging Rats. , 0, .		35
56	Body Fat at Puberty in Rats: Alteration by Changes in Diet. Pediatric Research, 1979, 13, 7-9.	1.1	33
57	Single, escalating dose pharmacokinetics, safety and food effects of a new oral androgen dimethandrolone undecanoate in man: a prototype oral male hormonal contraceptive. Andrology, 2014, 2, 579-587.	1.9	33
58	The Potent Humanin Analogue (HNG) Protects Germ Cells and Leucocytes While Enhancing Chemotherapy-Induced Suppression of Cancer Metastases in Male Mice. Endocrinology, 2015, 156, 4511-4521.	1.4	33
59	Combined nestorone–testosterone gel suppresses serum gonadotropins to concentrations associated with effective hormonal contraception in men. Andrology, 2019, 7, 878-887.	1.9	33
60	Turnover of nonessential fatty acids in cardiolipin from the rat heart. Journal of Lipid Research, 2011, 52, 2226-2233.	2.0	28
61	Recruitment and Screening for the Testosterone Trials. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2015, 70, 1105-1111.	1.7	28
62	Characteristics associated with suppression of spermatogenesis in a male hormonal contraceptive trial using testosterone and Nestorone (sup) $\hat{A}^{\otimes}$ (sup) gels. Andrology, 2013, 1, 899-905.	1.9	27
63	Association of endogenous testosterone with subclinical atherosclerosis in men: the multiâ€ethnic study of atherosclerosis. Clinical Endocrinology, 2016, 84, 700-707.	1.2	25
64	Testosterone protects high-fat/low-carbohydrate diet-induced nonalcoholic fatty liver disease in castrated male rats mainly via modulating endoplasmic reticulum stress. American Journal of Physiology - Endocrinology and Metabolism, 2018, 314, E366-E376.	1.8	25
65	Advances in male hormone substitution therapy. Expert Opinion on Pharmacotherapy, 2005, 6, 1493-1506.	0.9	23
66	Dietary Fat Modulates the Testosterone Pharmacokinetics of a New Selfâ€Emulsifying Formulation of Oral Testosterone Undecanoate in Hypogonadal Men. Journal of Andrology, 2012, 33, 1282-1290.	2.0	23
67	Daily Oral Administration of the Novel Androgen $11\hat{l}^2$ -MNTDC Markedly Suppresses Serum Gonadotropins in Healthy Men. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e835-e847.	1.8	23
68	Emerging medication for the treatment of male hypogonadism. Expert Opinion on Emerging Drugs, 2016, 21, 255-266.	1.0	22
69	A 52-Week Study of Dose Adjusted Subcutaneous Testosterone Enanthate in Oil Self-Administered via Disposable Auto-Injector. Journal of Urology, 2019, 201, 587-594.	0.2	22
70	Temporal and stage-specific changes in spermatogenesis of rat after gonadotropin deprivation by a potent gonadotropin-releasing hormone antagonist treatment. , 0, .		22
71	Levonorgestrel Implants (Norplant II) for Male Contraception Clinical Trials: Combination with Transdermal and Injectable Testosterone. , 0, .		22
72	Testosterone Doseâ€Dependency of Sexual and Nonsexual Behaviors in The Gonadotropinâ€Releasing Hormone Antagonistâ€Treated Male Rat. Journal of Andrology, 1989, 10, 167-173.	2.0	20

#	Article	IF	Citations
73	Prostate-Specific Antigen Levels During Testosterone Treatment of Hypogonadal Older Men: Data from a Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 6238-6246.	1.8	20
74	Male hormonal contraception: hope and promise. Lancet Diabetes and Endocrinology, the, 2017, 5, 214-223.	5.5	19
75	A new oral testosterone undecanoate therapy comes of age for the treatment of hypogonadal men. Therapeutic Advances in Urology, 2020, 12, 175628722093723.	0.9	17
76	Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel. Aging Male, 2003, 6, 207-211.	0.9	17
77	Validity and Clinically Meaningful Changes in the Psychosexual Daily Questionnaire and Derogatis Interview for Sexual Function Assessment: Results From the Testosterone Trials. Journal of Sexual Medicine, 2018, 15, 997-1009.	0.3	13
78	Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel. Aging Male, 2003, 6, 207-11.	0.9	13
79	Testosterone Replacement Therapy in Hypogonadal Men. Endocrinology and Metabolism Clinics of North America, 2022, 51, 77-98.	1.2	10
80	Reflections on the T Trials. Andrology, 2020, 8, 1512-1518.	1.9	8
81	Dimethandrolone Undecanoate, a Novel, Nonaromatizable Androgen, Increases P1NP in Healthy Men Over 28 Days. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e171-e181.	1.8	8
82	Follow-up intervals in patients with Cushing's disease: recommendations from a panel of experienced pituitary clinicians. Pituitary, 2017, 20, 422-429.	1.6	7
83	Continuing the search for a hormonal male contraceptive. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2020, 66, 83-94.	1.4	7
84	Acceptability of the oral hormonal male contraceptive prototype, $11\hat{l}^2$ -methyl-19-nortestosterone dodecylcarbonate ( $11\hat{l}^2$ -MNTDC), in a 28-day placebo-controlled trial. Contraception, 2021, 104, 531-537.	0.8	7
85	Biomarkers and Noncalcified Coronary Artery Plaque Progression in Older Men Treated With Testosterone. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2142-2149.	1.8	4
86	Corifollitropin Alfa Combined With Human Chorionic Gonadotropin in Adolescent Boys With Hypogonadotropic Hypogonadism. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 2036-2046.	1.8	4
87	Comparison of metabolic effects of the progestational androgens dimethandrolone undecanoate and 11βâ€MNTDC in healthy men. Andrology, 2021, 9, 1526-1539.	1.9	3
88	Relation between Retinopathy and Progression of Coronary Artery Calcium in Individuals with Versus Without Diabetes Mellitus (From the Multi–Ethnic Study of Atherosclerosis). American Journal of Cardiology, 2021, 149, 1-8.	0.7	3
89	Should hypogonadal men who are suboptimally responsive to testosterone gel switch to another gel preparation?. Nature Reviews Urology, 2008, 5, 190-191.	1.4	1
90	Evaluation of the infertile couple. Endocrinology and Metabolism Clinics of North America, 1988, 17, 301-37.	1.2	1

#	Article	IF	CITATIONS
91	405 MINOCYCLINE THROUGH SUPPRESSION OF CYTOCHROME C AND DIABLO RELEASE ATTENUATES MALE GERM CELL APOPTOSIS AFTER HORMONE WITHDRAWAL. Journal of Investigative Medicine, 2005, 53, S149.3-S149.	0.7	0
92	Testosterone levels in benign prostatic hyperplasia: sexual function and response to therapy with dutasteride. Nature Reviews Urology, 2006, 3, 528-529.	1.4	0
93	Apoptotic Signaling in Male Germ Cells. , 0, , 283-294.		0
94	What to Measure: Testosterone or Free Testosterone?. , 2021, , 1-13.		0
95	MALE REPRODUCTIVE PHYSIOLOGY. Japanese Journal of Urology, 1990, 81, 1980-1981.	0.0	0
96	Concanavalin A-Immobilized Glycoprotein Antigen for Immunoaffinity Purification of Antiserum. Clinical Chemistry, 1992, 38, 2143-2143.	1.5	0
97	OR16-1 Best of The Journal of Clinical Endocrinology & Metabolism: Macimorelin as a Diagnostic Test for Adult GH Deficiency. Journal of the Endocrine Society, 2019, 3, .	0.1	0